(Total Views: 457)
Posted On: 09/01/2019 5:46:01 PM
Post# of 36564
It’s more clear in the 8k from January what to expect although it seems apparent that timelines are now different.
In addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the following cash payments, with the proceeds intended to be used for specific purposes, as noted:
$3,450,000 to initiate pre-clinical activities on or before January 15, 2018.
$2,000,000 to initiate patient recruitment activities on or before May 1, 2019.
$3,000,000 to initiate a first-in-human pilot study on or before September 1, 2019.
$5,000,000 to initiate a human pivotal study on or before February 1, 2020.
$1,150,000 to submit a 510(k) de novo submission to the FDA on or about February 1, 2021.
In addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the following cash payments, with the proceeds intended to be used for specific purposes, as noted:
$3,450,000 to initiate pre-clinical activities on or before January 15, 2018.
$2,000,000 to initiate patient recruitment activities on or before May 1, 2019.
$3,000,000 to initiate a first-in-human pilot study on or before September 1, 2019.
$5,000,000 to initiate a human pivotal study on or before February 1, 2020.
$1,150,000 to submit a 510(k) de novo submission to the FDA on or about February 1, 2021.
(1)
(0)
